Asia-Pacific Insulin Delivery Devices Market Outlook, 2028

The Asia Pacific region has witnessed a significant increase in the prevalence of diabetes. Factors such as changing lifestyles, urbanization, and dietary habits have contributed to a rise in diabetes cases. There has been a growing awareness of diabetes and its management among both healthcare professionals and patients. This increased awareness has led to earlier diagnosis and treatment initiation, thereby driving the demand for insulin delivery devices. As economies in the Asia Pacific region continue to grow, disposable income levels have also risen. This increase in disposable income allows individuals to afford advanced and more convenient insulin delivery devices. The aging population in many countries contributes to the overall increase in chronic diseases, including diabetes. Older individuals may require insulin therapy, contributing to the demand for insulin delivery devices. Moreover, as governments continue to prioritize healthcare, channelling resources into the expansion and improvement of healthcare infrastructure, there exists a conducive environment for the diagnosis, treatment, and management of diabetes. The industry is witnessing a notable shift in patient preferences towards non-invasive options, with a particular emphasis on minimizing the impact of insulin therapy on daily life. Manufacturers are responding to this demand by developing innovative, patient-friendly devices, ranging from discreet wearable options to technologically sophisticated yet user-friendly insulin pens. Against this backdrop, the Asia Pacific insulin delivery devices market stands as a testament to the intersection of medical advancements, economic growth, and a collective commitment to addressing the evolving healthcare needs of the region's population. According to the research report, "Asia-Pacific Insulin Delivery Devices Market Outlook, 2028," published by Bonafide Research, the market is anticipated to grow at above 9% CAGR by 2023–28. The integration of digital technologies into insulin delivery devices is a prominent trend in the Asia Pacific market. Smart insulin pens and continuous glucose monitoring systems are gaining popularity, offering real-time data, connectivity, and enhanced user engagement. These technologies empower individuals with diabetes to monitor their blood glucose levels more effectively and make informed decisions about insulin dosage adjustments. The connectivity features enable healthcare providers to remotely monitor patients, facilitating timely interventions and personalized care. This trend not only improves the precision of insulin delivery but also contributes to better overall diabetes management. Wearable insulin delivery devices are emerging as a distinct trend in the Asia Pacific market. These devices, ranging from insulin patches to wearable pumps, offer convenience, discretion, and improved adherence to treatment regimens. Wearable devices provide a continuous and controlled release of insulin, reducing the need for frequent injections and offering a more seamless integration of diabetes management into daily life. As technology advances, the market is witnessing the development of smaller, more user-friendly wearable devices that cater to the evolving preferences of individuals managing diabetes in the region. The adoption of telehealth and remote patient monitoring is on the rise in the Asia Pacific region, influencing how insulin delivery devices are utilized and managed. Telehealth platforms enable remote consultations between healthcare providers and patients, facilitating on-going monitoring of blood glucose levels and insulin therapy adjustments. This trend is particularly significant in geographically diverse regions, ensuring that individuals in remote areas have access to timely and specialized diabetes care. The integration of telehealth solutions enhances the overall efficiency and effectiveness of insulin delivery management.

The Asia Pacific insulin delivery devices market exhibits diverse dynamics across key countries, with significant variations in healthcare infrastructure, economic development, and regulatory landscapes. In China, the market is influenced by a large diabetic population and a government focus on healthcare reform. The rising prevalence of diabetes has driven the demand for insulin delivery devices, with a particular emphasis on cost-effective solutions to cater to the vast patient pool. Japan, on the other hand, showcases a mature healthcare system with a strong emphasis on technological innovation. The market in Japan is characterized by a high adoption rate of advanced insulin delivery technologies, including smart pens and connected devices, reflecting the country's inclination towards cutting-edge healthcare solutions. In India, where diabetes is on the rise, the market for insulin delivery devices is influenced by factors such as the increasing awareness of diabetes management, improving healthcare infrastructure, and a growing middle-class population. Affordability and accessibility are key considerations in this market, driving the demand for cost-effective yet technologically advanced insulin delivery options. In terms of Product segment market is categorised into Insulin Pens, Insulin Pumps, Insulin Pen Needles, Insulin Syringes and Others Insulin Delivery Devices (Insulin transdermal patches, insulin inhalers, and insulin jet injection). Insulin pumps offer a convenient and discreet way for individuals with diabetes to manage their insulin levels. They provide continuous subcutaneous insulin delivery, eliminating the need for multiple daily injections. This convenience aligns with the desire for improved quality of life and better adherence to insulin therapy. Many individuals with diabetes express a preference for pump therapy due to its convenience and lifestyle benefits. Insulin pumps reduce the need for multiple daily injections, offering a discreet and user-friendly alternative that fits more seamlessly into daily life. Insulin pumps are often favoured in pediatric diabetes management due to their ease of use and the potential to improve adherence in younger populations. Family preferences for the convenience and control offered by pump therapy can influence its adoption in pediatric care. In addition, based on indication the market is divided into Diabetes, Pregnancy, Cardiovascular Disorders & Hypertension, Respiratory Diseases, Hearing Disorders, Cancer, Movement Disorders, Wound Care and Other Indications (sleep disorders, kidney disorders, neurovascular diseases, and HIV). Cancer patients, particularly those with certain types of tumors, may experience hyperglycemia as a result of the disease or cancer treatments. Hyperglycemia can be associated with insulin resistance and an increased need for insulin to manage blood glucose levels effectively. Malnutrition is common in cancer patients, and cancer-related malnutrition can contribute to hyperglycemia. Insulin therapy may be required to manage blood glucose levels in these patients and insulin delivery devices can provide a more controlled and precise means of administration. Based on end user the market is majorly divided into Home Care, Hospitals & Clinics and Others. The Asia Pacific region has witnessed an increase in the prevalence of chronic conditions such as diabetes. As these conditions often require on-going management and insulin therapy, the home care segment becomes crucial for providing convenient and accessible solutions for patients. Patients often prefer receiving care in the comfort of their homes, especially for chronic conditions that require long-term management. Home care allows individuals to have greater autonomy over their treatment and promotes a sense of independence. Continuous advancements in insulin delivery devices have made it easier for patients to manage their conditions at home. User-friendly devices, such as insulin pens and pumps, provide convenience and simplicity, contributing to the preference for home-based care. The aging population in the Asia Pacific region has contributed to an increased focus on home care. Older adults, who may have chronic conditions requiring insulin therapy, often prefer receiving care at home, and insulin delivery devices that are easy to use support this preference. Patient education programs and initiatives that empower individuals to self-manage their conditions contribute to the success of home-based care. Training patients on the proper use of insulin delivery devices enhances their confidence in managing their health at home. The COVID-19 pandemic has had a range of effects on healthcare systems, including disruptions to the production and supply chains of medical devices. In the short term, lockdowns, restrictions on movement, and disruptions to international trade may have affected the manufacturing and distribution of insulin delivery devices. This could potentially lead to challenges in the availability and accessibility of these devices in some areas. The rollout of COVID-19 vaccines and the pace of economic recovery in the Asia Pacific region can play a significant role in shaping the post-pandemic landscape. Successful vaccination campaigns and economic rebound may contribute to increased stability and confidence in healthcare systems, potentially positively impacting the insulin delivery devices market. Many people with diabetes were reluctant to visit healthcare providers for routine check-ups and device refills due to concerns about exposure to the virus. Companies Covered in this report: Novo Nordisk A/S , Sanofi S.A., Eli Lilly and Company, Medtronic plc , Terumo Corporation, Becton, Dickinson and Company, Insulet Corporation, Biocon Limited ,Wockhardt Ltd., B. Braun Melsungen AG, SOOIL Development Co., Ltd.

Considered in this report: • Geography: Asia Pacific • Historic year: 2017 • Base year: 2022 • Estimated year: 2023 • Forecast year: 2028 Aspects covered in this report: • Asia Pacific Insulin Delivery Devices market with its value and forecast along with its segments • Country-wise Insulin Delivery Devices market analysis • Various drivers and challenges • On-going trends and developments • Top profiled companies • Strategic recommendation Country Covered in this report: • China • Japan • India • Australia • South Korea By Product • Insulin Pens • Insulin Pumps • Insulin Pen Needles • Insulin Syringes • Others Insulin Delivery Devices (Insulin transdermal patches, insulin inhalers, insulin jet injection) By Indication • Diabetes • Pregnancy • Cardiovascular Disorders & Hypertension • Respiratory Diseases • Hearing Disorders • Cancer • Movement Disorders • Wound Care • Other Indications (sleep disorders, kidney disorders, neurovascular diseases, and HIV) By End User • Home Care • Hospitals & Clinics • Others The approach of the report: This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources. Intended audience: This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Tea industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.